Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study.
Journal
Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
23
11
2021
accepted:
15
02
2022
pubmed:
27
2
2022
medline:
25
8
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
The outcomes of endoscopic submucosal dissection (ESD) for T1b esophageal cancer (EC) and its recurrence rates remain unclear in the West. Using a multicenter cohort, we evaluated technical outcomes and recurrence rates of ESD in the treatment of pathologically staged T1b EC. We included patients who underwent ESD of T1b EC at 7 academic tertiary referral centers in the United States (n = 6) and Brazil (n = 1). We analyzed demographic, procedural, and histopathologic characteristics and follow-up data. Time-to-event analysis was performed to evaluate recurrence rates. Sixty-six patients with pathologically staged T1b EC after ESD were included in the study. A preprocedure staging EUS was available in 54 patients and was Tis/T1a in 27 patients (50%) and T1b in 27 patients (50%). En-bloc resection rate was 92.4% (61/66) and R0 resection rate was 54.5% (36/66). Forty-nine of 66 patients (74.2%) did not undergo surgery immediately after resection and went on to surveillance. Ten patients had ESD resection within the curative criteria, and no recurrences were seen in a 13-month (range, 3-18.5) follow-up period in these patients. Ten of 39 patients (25.6%) with noncurative resections had residual/recurrent disease. Of the 10 patients with noncurative resection, local recurrence alone was seen in 5 patients (12.8%) and metastatic recurrence in 5 patients (12.8%). On univariate analysis, R1 resection had a higher risk of recurrent disease (hazard ratio, 6.25; 95% confidence interval, 1.29-30.36; P = .023). EUS staging of T1b EC has poor accuracy, and a staging ESD should be considered in these patients. ESD R0 resection rates were low in T1b EC, and R1 resection was associated with recurrent disease. Patients with noncurative ESD resection of T1b EC who cannot undergo surgery should be surveyed closely, because recurrent disease was seen in 25% of these patients.
Sections du résumé
BACKGROUND AND AIMS
The outcomes of endoscopic submucosal dissection (ESD) for T1b esophageal cancer (EC) and its recurrence rates remain unclear in the West. Using a multicenter cohort, we evaluated technical outcomes and recurrence rates of ESD in the treatment of pathologically staged T1b EC.
METHODS
We included patients who underwent ESD of T1b EC at 7 academic tertiary referral centers in the United States (n = 6) and Brazil (n = 1). We analyzed demographic, procedural, and histopathologic characteristics and follow-up data. Time-to-event analysis was performed to evaluate recurrence rates.
RESULTS
Sixty-six patients with pathologically staged T1b EC after ESD were included in the study. A preprocedure staging EUS was available in 54 patients and was Tis/T1a in 27 patients (50%) and T1b in 27 patients (50%). En-bloc resection rate was 92.4% (61/66) and R0 resection rate was 54.5% (36/66). Forty-nine of 66 patients (74.2%) did not undergo surgery immediately after resection and went on to surveillance. Ten patients had ESD resection within the curative criteria, and no recurrences were seen in a 13-month (range, 3-18.5) follow-up period in these patients. Ten of 39 patients (25.6%) with noncurative resections had residual/recurrent disease. Of the 10 patients with noncurative resection, local recurrence alone was seen in 5 patients (12.8%) and metastatic recurrence in 5 patients (12.8%). On univariate analysis, R1 resection had a higher risk of recurrent disease (hazard ratio, 6.25; 95% confidence interval, 1.29-30.36; P = .023).
CONCLUSIONS
EUS staging of T1b EC has poor accuracy, and a staging ESD should be considered in these patients. ESD R0 resection rates were low in T1b EC, and R1 resection was associated with recurrent disease. Patients with noncurative ESD resection of T1b EC who cannot undergo surgery should be surveyed closely, because recurrent disease was seen in 25% of these patients.
Identifiants
pubmed: 35217020
pii: S0016-5107(22)00123-7
doi: 10.1016/j.gie.2022.02.018
pmc: PMC9488538
mid: NIHMS1831912
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-453Subventions
Organisme : NCI NIH HHS
ID : P50 CA150964
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Endoscopy. 2022 May;54(5):439-446
pubmed: 34450667
Gastrointest Endosc. 2020 Jan;91(1):55-65.e2
pubmed: 31445039
Gastrointest Endosc. 2020 Dec;92(6):1187-1189
pubmed: 33236991
BMC Gastroenterol. 2021 Aug 3;21(1):308
pubmed: 34344303
Gastroenterology. 2019 Aug;157(2):382-390.e3
pubmed: 31014996
Ann Thorac Surg. 2017 May;103(5):1661-1667
pubmed: 28385375
VideoGIE. 2021 May 26;6(8):342-343
pubmed: 34401626
Clin Gastroenterol Hepatol. 2022 Jan;20(1):65-73.e1
pubmed: 33220523
Endoscopy. 2022 Jun;54(6):531-541
pubmed: 34592769
Clin Transl Gastroenterol. 2020 Aug;11(8):e00188
pubmed: 32955196
Sci Rep. 2021 Mar 22;11(1):6554
pubmed: 33753766
Endoscopy. 2009 Sep;41(9):751-7
pubmed: 19693750
Thorac Cancer. 2020 May;11(5):1121-1128
pubmed: 32154652
Gastroenterology. 2000 Apr;118(4):670-7
pubmed: 10734018
Ann Surg. 2011 Feb;253(2):271-8
pubmed: 21119508
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Clin Gastroenterol Hepatol. 2019 Jan;17(1):16-25.e1
pubmed: 30077787
Gastrointest Endosc. 2019 Jun;89(6):1120-1128
pubmed: 30576649
Gastroenterology. 2021 Dec;161(6):2030-2040.e1
pubmed: 34689964
Am J Gastroenterol. 2015 Jun;110(6):784-91
pubmed: 25623656
Gastroenterology. 2014 Mar;146(3):652-660.e1
pubmed: 24269290
Dig Endosc. 2020 Mar;32(3):346-354
pubmed: 31306525
Endoscopy. 2017 Feb;49(2):191-198
pubmed: 28122386
Gastrointest Endosc. 2017 Oct;86(4):600-607
pubmed: 27688205
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e700-e708
pubmed: 34091478
Gastrointest Endosc. 2020 Jul;92(1):31-39.e1
pubmed: 31953189
Gastroenterology. 2020 Feb;158(3):760-769
pubmed: 31730766
Gastrointest Endosc. 2021 Apr;93(4):888-898.e1
pubmed: 32763242
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Matrix Biol. 2017 Jan;57-58:178-189
pubmed: 28025167
Gastrointest Endosc. 2017 Nov;86(5):779-791
pubmed: 28713066
Endoscopy. 2015 Sep;47(9):829-54
pubmed: 26317585
Clin Gastroenterol Hepatol. 2019 Jan;17(1):73-81.e3
pubmed: 29704682
Ann Thorac Surg. 2015 Nov;100(5):1812-6
pubmed: 26233274
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593